-Renee D Wright Researcher Activity Profile

Research Author Detailed Information 

Renee D Wright Publication Rate By Year

Renee D Wright has published 7 paper(s) in 1949, 1 paper(s) in 1965, 1 paper(s) in 2006, 2 paper(s) in 2007, 5 paper(s) in 2008, for a total of 16 research publications in total.

Renee D Rd Wright Author Information

LAST NAME: wright

FIRST NAME: Renee D

INITIALS: rd

AFFILIATION:

Papers

Renee D Wright's Publication Record

1. Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma. Year Published: 2007
Department of Pediatric Oncology, Dana-Farber Cancer Institute and Children's Hospital Boston, Harvard Medical School, Boston, Massachusetts, United States of America.
2. Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity. Year Published: 2006
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA. Ellen_weisberg@dfci.harvard.edu
3. Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells. Year Published: 2007
Department of Adult Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA.
4. Sodium potassium balance in cells. Year Published: 1949
5. Studies on the growth inhibitor fraction of Lima beans and isolation of a crystalline heat-stable trypsin inhibitor. Year Published: 1949
6. Stevens-Johnson syndrome, with case report. Year Published: 1949
7. Treatment as a factor in the control of the venereal diseases. Year Published: 1949
8. Treatment as a factor in the control of the venereal diseases. Year Published: 1949
9. MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: development of a model for rapid therapeutic assessment. Year Published: 2008
1Division of Hematology/Oncology, Children's Hospital, Boston, MA, USA;
10. Treatment as a factor in the control of the venereal diseases. Year Published: 1949
11. MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: development of a model for rapid therapeutic assessment. Year Published: 2008
1Division of Hematology/Oncology, Children's Hospital, Boston, MA, USA;
12. MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: development of a model for rapid therapeutic assessment. Year Published: 2008
Division of Hematology/Oncology, Children's Hospital, Boston, MA 02215, USA.
13. EXPERIMENTAL AND CLINICAL BARBITURATE ANTAGONISM. Year Published: 1965
14. Treatment as a factor in the control of the venereal diseases. Year Published: 1949
15. Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells. Year Published: 2008
16. Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells. Year Published: 2008
Department of Medical Oncology/Hematologic Neoplasia, Dana-Farber Cancer Institute, Boston, MA 02115, USA.